This is a joint statement from TAG and Health GAP October 16, 2019 – Although Speaker Nancy Pelosi’s bill to increase affordable access to medicines in the U.S., H.R. 3, offers halting, partial steps to reduce drug prices for some…
June 2013 By Karyn Kaplan As rich countries prepare for a hepatitis C virus (HCV) treatment revolution, people in low- and middle-income countries (LMICs) remain without access to information, prevention tools, diagnostics, care, and treatment. A growing movement of global…
Streamlining HCV Treatment By Tracy Swan Treatment for hepatitis C virus (HCV) is becoming simpler, shorter, and more effective. All-oral combinations of direct-acting antivirals (DAAs) have pushed cure rates in HCV genotype 1 to over 90 percent. Still, we are…
June 2013 By Tracy Swan Thanks to Jules Levin The pace of, and progress in, hepatitis C virus (HCV) drug development are astonishing. In April 2011, proof-of-concept for safe, effective, peginterferon-free HCV treatment was announced. Since then, numerous trials have…
By Karyn Kaplan and Tracy Swan How can governments and donors effectively address HCV if pharma refuses to drop drug prices? —Paata Sabelashvili, Activist, Georgian Harm Reduction Network Keeping up with the rapid pace of hepatitis C drug development,…
July 2014 By Tracy Swan Thanks to Jules Levin This update includes presentations from the American Association for the Study of Liver Diseases (AASLD) Meeting, the Conference on Retroviruses and Opportunistic Infections (CROI), the European Association for the Study of…
July 2014 By Tracy Swan BONANZA! The Gold Rush Is Under Way The direct-acting antiviral (DAA) era officially began in late 2013, with approval of the first all-oral treatment for hepatitis C virus (HCV) genotypes 2 and 3. A hefty…